Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Why reform needs to start at cancer care

Brian Klepper, PhD
Meds
October 29, 2015
92 Shares
Share
Tweet
Share

Recently, the clinically positive results from the CLEOPATRA oncology trial were released, showing that pertuzumab, when added to docetaxel and trastuzumab as first-line chemotherapy, produces an average survival benefit of 15.7 months in HER2 positive breast cancer patients.

That good news notwithstanding, the authors calculated that Genentech’s price for adding pertuzumab to gain one quality adjusted life year is a breathtaking $713,219. In dry academic language, the authors dropped a bombshell conclusion. “The addition of pertuzumab to a standard regimen … for treatment of metastatic HER2-overexpressing breast cancer is unlikely to provide reasonable value for money spent in the United States compared with other interventions generally deemed cost effective. This analysis highlights the economic challenges of extending life for patients with non-curable disease.

Drugs only consume about a quarter of cancer costs. The other three-quarters are distributed between physicians, outpatient facilities and hospitals, delivering such lucrative returns that hospitals are rushing to get in on the action. As many as one in four U.S. hospitals are building new cancer centers now. Hospitals’ acquisitions of oncology practices have accelerated, in part because they can charge almost twice as much as physician practices for chemotherapies and other cancer drugs.

Change has been simmering in oncology for some time, but now it is coming to a boil. It is clear that cancer professionals — physicians, researchers and society execs — have felt uncomfortably complicit with a paradigm that too often extracts exorbitant sums of money for miniscule clinical benefit. In the past, it has been all but forbidden to consider cost when making clinical decisions. But even in our ossified system, clinicians have been so offended by excessive cost and nominal benefit that they have begun to mobilize.

Last July, 118 leading oncologists from major cancer centers signed an open letter in the Mayo Clinic Proceedings, condemning the harm that excessive cancer drug pricing exerts on patients and families, and urging new cost control regulations. They note, “There is no relief in sight because drug companies keep challenging the market with even higher prices. This raises the question of whether current pricing of cancer drugs is based on reasonable expectation of return on investment or whether it is based on what prices the market can bear.”

In the past, drug manufacturers would no doubt have shrugged, but they’re almost certainly carefully watching this development. Three years ago Memorial Sloan Kettering very publicly refused to carry Zaltrap, a colorectal cancer drug that performs similarly to another medicine, Avastin, but at twice the price. Faced with a public relations disaster, Sanofi immediately caved, halving Zaltrap’s price rather than face the prospect of other cancer centers following suit. Market forces can work.

Cancer’s intensifying rush of new treatments and extreme cost has moved leading oncology organizations to go a step further. They’re developing objective methodologies for valuing clinical treatments. Last June, the American Society of Clinical Oncology published a statement describing a draft “conceptual framework” for assessing the value of cancer therapies based on treatment benefits, toxicities and cost. Frameworks with similar intent are under development by the National Comprehensive Cancer Network, Memorial Sloan Kettering’s Center for Health Policy and Outcomes and others.

With multiple efforts underway to address a common problem, a call for a single national (or global) value framework was inevitable. Daniel Goldstein MD, an Atlanta researcher, wrote, “There is currently a crucial step in the drug development and approval process that is missing — an evaluation of cost and value.” In other words, Dr. Goldstein and his team urged the Food and Drug Administration to develop, refine and adopt a framework that establishes value-based pricing for all oncology drugs seeking approval.

Of course, tools that clarify value promise to be hugely useful in cancer care, where patients and purchasers face questionable treatments and immense costs. But these tools are also desperately needed in the rest of health care. Consider the specialty drug market, where U.S. pricing is rising almost 20 times faster than conventional drugs, generally without being tethered to an identifiable rationale. Most of health care — cardiovascular care, musculoskeletal care, dialysis, imaging, hospital pricing — suffers from rampant excess and can only benefit from credible assessments of value.

Cancer care is a concentrated microcosm of broader health industry practices because it resides at the nexus of aspirational technologies, enormous costs, hope, and death. The cancer community’s pioneering valuation efforts and pushbacks against profiteering are remarkable because they offer sorely-needed context for clinical and financial decision-making, reflecting the imperative that we can’t afford poor cancer solutions much longer. The rest of health care can’t be far behind.

Brian Klepper is a health care analyst and principal, Health Value Direct.  This article originally appeared in the Health Care Blog.

Prev

My patients have shown me that medicine is a universally spoken language

October 29, 2015 Kevin 1
…
Next

Beyond the death count: The psychological casualties of mass violence

October 30, 2015 Kevin 0
…

Tagged as: Oncology/Hematology

Post navigation

< Previous Post
My patients have shown me that medicine is a universally spoken language
Next Post >
Beyond the death count: The psychological casualties of mass violence

More by Brian Klepper, PhD

  • a desk with keyboard and ipad with the kevinmd logo

    The FDA’s epic regulatory failure

    Brian Klepper, PhD
  • a desk with keyboard and ipad with the kevinmd logo

    Will fee for service ever go away?

    Brian Klepper, PhD
  • a desk with keyboard and ipad with the kevinmd logo

    Stop pursuing self-pay patients as a windfall opportunity

    Brian Klepper, PhD

Related Posts

  • Obstruction of medical justice: How health care fails patients with cancer

    Miriam A. Knoll, MD
  • Despite progress in cancer care, cost and equity challenges still must be addressed

    David M. Aboulafia, MD
  • A letter to a cancer patient in palliative care

    Alison Vasa
  • Cancer care costs everyone too much. What can we do about it?

    Andrew Hertler, MD
  • When breast cancer screening guidelines conflict: Some patients face real consequences

    Leda Dederich
  • 4 disturbing trends in health care

    Praveen Suthrum

More in Meds

  • Telemedicine in the opioid crisis: a game-changer threatened by DEA regulations

    Julie Craig, MD
  • The real cause of America’s opioid crisis: Doctors are not to blame

    Richard A. Lawhern, PhD
  • Can personalized medicine live up to its hype in health care?

    Ketan Desai, MD, PhD
  • The effects of the nationwide stimulant shortage on a private psychiatry practice

    Christine Tran-Boynes, DO
  • Why North American medical cannabis can’t compete globally

    Michael Sassano
  • How were we duped and what can we do about the opioid overdose crisis?

    Ronald A. Zent, MD
  • Most Popular

  • Past Week

    • The real cause of America’s opioid crisis: Doctors are not to blame

      Richard A. Lawhern, PhD | Meds
    • It’s time for C-suite to contract directly with physicians for part-time work

      Aaron Morgenstein, MD & Corinne Sundar Rao, MD | Physician
    • The struggle to fill emergency medicine residency spots: Exploring the factors behind the unfilled match

      Katrina Gipson, MD, MPH | Physician
    • What is driving physicians to the edge of despair?

      Edward T. Creagan, MD | Physician
    • Beyond the disease: the power of empathy in health care

      Nana Dadzie Ghansah, MD | Physician
    • The psychoanalytic hammer: lessons in listening and patient-centered care

      Greg Smith, MD | Conditions
  • Past 6 Months

    • The real cause of America’s opioid crisis: Doctors are not to blame

      Richard A. Lawhern, PhD | Meds
    • Nobody wants this job. Should physicians stick around?

      Katie Klingberg, MD | Physician
    • The vital importance of climate change education in medical schools

      Helen Kim, MD | Policy
    • The fight for reproductive health: Why medication abortion matters

      Catherine Hennessey, MD | Physician
    • Resetting the doctor-patient relationship: Navigating the challenges of modern primary care

      Jeffrey H. Millstein, MD | Physician
    • The Titanic sinking: a metaphor for the impending collapse of medicine

      Aaron Morgenstein, MD & Corinne Sundar Rao, MD & Shreekant Vasudhev, MD | Physician
  • Recent Posts

    • Surviving clinical rounds: tips and tales from a pediatric hematologist-oncologist [PODCAST]

      The Podcast by KevinMD | Podcast
    • The harmful effects of shaming patients for self-education

      Maryanna Barrett, MD | Physician
    • The power of self-appreciation: Why physicians need to start acknowledging their own contributions

      Wendy Schofer, MD | Physician
    • The endless waves of chronic illness

      Michele Luckenbaugh | Conditions
    • Skydiving and surgery: How one doctor translates high-stress training to saving lives

      Alexandra Kharazi, MD | Physician
    • Telemedicine in the opioid crisis: a game-changer threatened by DEA regulations

      Julie Craig, MD | Meds

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 2 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

CME Spotlights

From MedPage Today

Latest News

  • Abortion Is Not Murder in the Eyes of the Law
  • Introducing Allergenic Foods Early Tied to a Reduction in Later Allergies
  • Isotretinoin REMS Still Needed, But Its Burden Could Be Reduced, FDA Staff Says
  • Children Do Well With Fewer Opiates After Surgery
  • High Out-of-Pocket Costs Tied to Less Follow-Up After Initial Mammography

Meeting Coverage

  • Children Do Well With Fewer Opiates After Surgery
  • Advances in Diagnosis and Management of Severe Cutaneous Adverse Reactions
  • Orismilast Clears Skin in Moderate-to-Severe Psoriasis
  • New Combinations Promising in Advanced Urothelial Carcinoma
  • No Survival Benefit With CRT Versus Chemo for Locally Advanced Endometrial Cancer
  • Most Popular

  • Past Week

    • The real cause of America’s opioid crisis: Doctors are not to blame

      Richard A. Lawhern, PhD | Meds
    • It’s time for C-suite to contract directly with physicians for part-time work

      Aaron Morgenstein, MD & Corinne Sundar Rao, MD | Physician
    • The struggle to fill emergency medicine residency spots: Exploring the factors behind the unfilled match

      Katrina Gipson, MD, MPH | Physician
    • What is driving physicians to the edge of despair?

      Edward T. Creagan, MD | Physician
    • Beyond the disease: the power of empathy in health care

      Nana Dadzie Ghansah, MD | Physician
    • The psychoanalytic hammer: lessons in listening and patient-centered care

      Greg Smith, MD | Conditions
  • Past 6 Months

    • The real cause of America’s opioid crisis: Doctors are not to blame

      Richard A. Lawhern, PhD | Meds
    • Nobody wants this job. Should physicians stick around?

      Katie Klingberg, MD | Physician
    • The vital importance of climate change education in medical schools

      Helen Kim, MD | Policy
    • The fight for reproductive health: Why medication abortion matters

      Catherine Hennessey, MD | Physician
    • Resetting the doctor-patient relationship: Navigating the challenges of modern primary care

      Jeffrey H. Millstein, MD | Physician
    • The Titanic sinking: a metaphor for the impending collapse of medicine

      Aaron Morgenstein, MD & Corinne Sundar Rao, MD & Shreekant Vasudhev, MD | Physician
  • Recent Posts

    • Surviving clinical rounds: tips and tales from a pediatric hematologist-oncologist [PODCAST]

      The Podcast by KevinMD | Podcast
    • The harmful effects of shaming patients for self-education

      Maryanna Barrett, MD | Physician
    • The power of self-appreciation: Why physicians need to start acknowledging their own contributions

      Wendy Schofer, MD | Physician
    • The endless waves of chronic illness

      Michele Luckenbaugh | Conditions
    • Skydiving and surgery: How one doctor translates high-stress training to saving lives

      Alexandra Kharazi, MD | Physician
    • Telemedicine in the opioid crisis: a game-changer threatened by DEA regulations

      Julie Craig, MD | Meds

MedPage Today Professional

An Everyday Health Property Medpage Today iMedicalApps
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Why reform needs to start at cancer care
2 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...